熱門資訊> 正文
EyePoint Pharmaceuticals GAAP每股收益为-0.58美元,收入为950万美元
2024-08-07 21:16
- EyePoint Pharmaceuticals press release (NASDAQ:EYPT): Q2 GAAP EPS of -$0.58.
- Revenue of $9.5M.
More on EyePoint Pharmaceuticals
- Seeking Alpha’s Quant Rating on EyePoint Pharmaceuticals
- Historical earnings data for EyePoint Pharmaceuticals
- Financial information for EyePoint Pharmaceuticals
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。